Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(80.0%)
N/A
1(20.0%)
5Total
Phase 3(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07050446Phase 3Completed

Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye

Role: lead

NCT06323395Phase 3Completed

Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

Role: lead

NCT05973305Phase 3Completed

Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

Role: lead

NCT05973318Phase 3Completed

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Role: lead

NCT05948800Not ApplicableUnknown

Impact of Nasal Isotonic Solution Irigation on Healthy Athletes' Nasal Flow and Nasal Obstruction Exercise Outcomes

Role: collaborator

All 5 trials loaded